673-a

673-A is an aldehyde dehydrogenase (ALDH1A) inhibitor that depletes CD133+ cancer stem cells (CSC) in ovarian cancer cell lines. 673-A triggers necroptosis in ovarian CSCs and induces expression of mitochondrial uncoupling proteins (UCP). 673-A also overcomes chemotherapy resistance in vivo.

Talazoparib (LT-673) 是一种 PARP 抑制剂，可以抑制 PARP 1和 PARP 2 (Ki=1.2/0.87 nM)，具有口服活性。Talazoparib 具有抗肿瘤活性，可以通过阻断 PARP 酶活性以及将 PARP 捕获在 DNA 损伤位点上来诱导肿瘤细胞死亡。

CM-675 是磷酸二酯酶 5 (PDE5)和I 类组蛋白去乙酰化酶 (HDAC1) 的选择性抑制剂，对 PDE5 和 HDAC1 的IC50 值分别为114 nM 和673 nM。CM-675 可用于阿尔兹海默症的研究。

Compound Fr13871是一个片段分子，CAS号为673-66-5，可作为分子拼接、扩展和修饰的重要骨架，为新型候选药物的设计与筛选提供结构基础与研究工具，常用于药物发现、药物合成等相关研究。

Amyloid-β (1-8, A2V) is a truncated form of amyloid-β (Aβ) that contains a valine to alanine substitution at position 2 of the Aβ numbering convention (Aβ A2V), which corresponds to position 673 of the amyloid precursor protein (APP) numbering convention (APP A673V). An Aβ (1-40) (Aβ40) A2V peptide increases the production of Aβ and the rate and amount of amyloid fibril formation in vitro, effects that can be reduced by coincubation with wild-type Aβ40. Aβ40 and Aβ42 levels are increased in CHO cells expressing the Aβ A2V mutation and in fibroblasts derived from patients with the Aβ A2V mutation. As a homozygous mutation, Aβ A2V is correlated with Alzheimer's disease with distinctive pathological features, but disease does not develop in patients with a heterozygous Aβ A2V mutation.

MY-673是CBSI（秋水仙碱结合位点抑制剂），可抑制微管蛋白聚合。该化合物还可阻断ERK信号通路，进而调节TGF-β/SMAD通路中的SMAD4蛋白表达。MY-673已经证实能在体内外有效抑制细胞的增殖和迁移，同时诱导apoptosis（细胞凋亡）。

Emerfetamab (AMG 673) 是一种具有延长半衰期的双特异性 T 细胞接合剂，能够同时结合CD33和CD3。该药通过将 T 细胞重定向至CD33+细胞，实现对急性髓系白血病 (AML) 母细胞的 T 细胞介导的细胞毒作用。